In vitro antimicrobial activity of a new antibiotic, MDL 62,879 (GE2270 A)
- 1 April 1993
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 37 (4) , 741-745
- https://doi.org/10.1128/aac.37.4.741
Abstract
MDL 62,879 (GE2270 A) is a new peptide antibiotic that inhibits protein synthesis through an interaction with elongation factor Tu. MDL 62,879 was very active against gram-positive clinical isolates, particularly staphylococci and enterococci, for which MICs for 90% of isolates were < or = 0.13 micrograms/ml. It was equally active against isolates resistant to beta-lactams, erythromycin, gentamicin, and glycopeptides. It also had activity against Mycobacterium tuberculosis. MDL 62,879 had moderate bactericidal activity against staphylococci.Keywords
This publication has 7 references indexed in Scilit:
- Faculty Opinions recommendation of Mutations of Bacteria from Virus Sensitivity to Virus Resistance.Published by H1 Connect ,2010
- In vitro activity of MDL 62,879 (GE2270 A) against aerobic gram-positive and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1993
- Inhibition of bacterial protein synthesis by elongation-factor-Tu-binding antibiotics MDL 62,879 and efrotomycinBiochemical Journal, 1992
- Vancomycin-resistant bacteria.1992
- Bacterial challenges and evolving antibacterial drug strategyPostgraduate Medical Journal, 1992
- Methicillin-resistant Staphylococcus aureus—a reappraisalJournal of Hospital Infection, 1991
- Antibiotic GE2270 A: A novel inhibitor of bacterial protein synthesis. I. Isolation and characterization.The Journal of Antibiotics, 1991